Versor Investments LP Buys New Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Versor Investments LP acquired a new stake in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 33,700 shares of the life sciences company's stock, valued at approximately $612,000.

A number of other hedge funds have also modified their holdings of IART. Blue Trust Inc. raised its stake in Integra LifeSciences by 100.5% in the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company's stock valued at $26,000 after purchasing an additional 444 shares during the last quarter. CWM LLC increased its position in Integra LifeSciences by 50.8% during the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company's stock worth $37,000 after purchasing an additional 425 shares in the last quarter. Northwest Investment Counselors LLC purchased a new position in shares of Integra LifeSciences in the 3rd quarter valued at $73,000. Canada Pension Plan Investment Board purchased a new stake in Integra LifeSciences during the 2nd quarter worth $114,000. Finally, Allspring Global Investments Holdings LLC increased its holdings in Integra LifeSciences by 58.0% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 4,662 shares of the life sciences company's stock valued at $136,000 after purchasing an additional 1,711 shares in the last quarter. 84.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

IART has been the topic of a number of recent research reports. BTIG Research raised shares of Integra LifeSciences from a "sell" rating to a "neutral" rating in a research report on Monday, October 7th. Truist Financial decreased their price objective on shares of Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating for the company in a research report on Monday, October 14th. Citigroup lifted their target price on Integra LifeSciences from $16.00 to $22.00 and gave the stock a "sell" rating in a research report on Tuesday, November 5th. JMP Securities reduced their price target on Integra LifeSciences from $40.00 to $35.00 and set a "market outperform" rating for the company in a report on Tuesday, July 30th. Finally, Bank of America dropped their price objective on Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating on the stock in a report on Monday, October 7th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $27.25.

Integra LifeSciences Stock Performance

Shares of NASDAQ IART traded down $0.04 during trading on Thursday, reaching $23.27. The stock had a trading volume of 727,881 shares, compared to its average volume of 1,101,799. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The stock has a market cap of $1.80 billion, a PE ratio of -258.53, a P/E/G ratio of 0.84 and a beta of 1.08. Integra LifeSciences Holdings Co. has a one year low of $16.81 and a one year high of $45.42. The firm's 50 day moving average price is $19.46 and its two-hundred day moving average price is $24.25.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm had revenue of $380.80 million during the quarter, compared to analyst estimates of $375.81 million. During the same quarter in the previous year, the firm earned $0.76 earnings per share. The firm's revenue for the quarter was down .4% compared to the same quarter last year. On average, research analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.